Results 191 to 200 of about 8,252,790 (324)
Anticancer Drug Approval in China: From Acceleration of Access to Certainty of Benefits. [PDF]
Zhang J.
europepmc +1 more source
Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials. [PDF]
Kanapuru B +11 more
europepmc +1 more source
UiO‐66(Zr) metal–organic frameworks are chemically stable, biocompatible, and highly tunable nanomaterials. Their modular structure enables controlled drug delivery, multimodal bioimaging, and light‐activated photodynamic therapy, supporting integrated diagnostic and therapeutic (theranostic) applications in cancer and biomedical research.
Veronika Huntošová +2 more
wiley +1 more source
Do Off-Label Drug Practices Argue Against FDA Efficacy Requirements? Testing an Argument by Structured Conversations with Experts [PDF]
The Food, Drug and Cosmetics Act of 1938 with amendments in 1962 is inconsistent regarding FDA certification of a drug’s efficacy. The act requires efficacy certification for the drug’s initial (“on-label”) uses, but does not require certification before
Klein, Daniel, Tabarrok, Alexander
core
Patient-Centered Drug Approval: The Role of Patient Advocacy in the Drug Approval Process.
T. J. Mattingly, L. Simoni-Wastila
semanticscholar +1 more source
Aquaporin‐3 and aquaporin‐5 impact the development of pancreatic ductal adenocarcinoma spheroids
Schematic representation of the role of aquaporin‐3 (AQP3) and aquaporin‐5 (AQP5) in pancreatic ductal adenocarcinoma (PDAC). Both proteins are upregulated in PDAC and are associated with tumor progression and metastatic potential. Silencing AQP3 or AQP5 in PDAC spheroids results in decreased diameter, area, and overall growth, underscoring their key ...
Catarina Pimpão +3 more
wiley +1 more source
Drug approval process for ovarian cancer
Prof Maria Paola Costi talks to ecancer at the 4th EUTROC meeting in Liverpool, UK about new drug developments and the main issues surrounding the drug approval process for ovarian cancer.
COSTI, Maria Paola
core
Assessment of the impact of Japanese-specific long-term safety data on new drug approval. [PDF]
Uzu S, Sekine S, Asano J, Ikuma M.
europepmc +1 more source
IGFBP4 knockdown (KD) impairs preadipocyte proliferation and is associated with IGF1R protein downregulation and attenuated AKT phosphorylation. The mechanisms by which IGFBP4 KD influences the IGF1R/AKT signaling pathway involve newly synthesized proteins and lysosomal degradation pathways. Created in BioRender.
Yujia Guo +6 more
wiley +1 more source
On the manipulability of approval voting and related scoring rules [PDF]
We characterize all preference profiles at which the approval (voting) rule is manipulable, under three extensions of preferences to sets of alternatives: by comparison of worstalternatives, best alternatives, or by comparison based on stochastic ...
Peters Hans, Storcken Ton, Roy Souvik
core

